ALX Oncology/$ALXO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ALX Oncology
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Ticker
$ALXO
Sector
Primary listing
Employees
43
Headquarters
Website
ALX Oncology Metrics
BasicAdvanced
$206m
-
-$1.34
0.45
-
Price and volume
Market cap
$206m
Beta
0.45
52-week high
$2.66
52-week low
$0.40
Average daily volume
1.2m
Financial strength
Current ratio
7.214
Quick ratio
7.003
Long term debt to equity
3.989
Total debt to equity
8.621
Interest coverage (TTM)
-57.62%
Profitability
EBITDA (TTM)
-87.347
Management effectiveness
Return on assets (TTM)
-36.76%
Return on equity (TTM)
-74.17%
Valuation
Price to book
1.36
Price to tangible book (TTM)
1.36
Price to free cash flow (TTM)
-1.298
Free cash flow yield (TTM)
-77.03%
Free cash flow per share (TTM)
-1.179
Growth
Earnings per share change (TTM)
-45.51%
3-year earnings per share growth (CAGR)
-24.99%
What the Analysts think about ALX Oncology
Analyst ratings (Buy, Hold, Sell) for ALX Oncology stock.
ALX Oncology Financial Performance
Revenues and expenses
ALX Oncology Earnings Performance
Company profitability
ALX Oncology News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs